{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:14:54Z","timestamp":1789748094605,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dysregulation of RNA binding protein (RBP) expression has been confirmed to be causally linked with tumorigenesis. The detailed biological effect and underlying mechanisms of the RBP GRSF1 in hepatocellular carcinoma (HCC) remain unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HCC cells with stable knockdown of GRSF1 were established using two sh-RNA-encoding lentiviruses. The functions of GRSF1 in HCC were explored using MTT, colony formation, flow cytometry, and Transwell assays and a xenograft model. Transcriptomic sequencing in GRSF1-deficient MHCC-97H cells was carried out to identify the downstream effector of GRSF1. The regulatory mechanisms among GRSF1, YY1 and miR-30e-5p were investigated via RNA immunoprecipitation, luciferase, RNA pull-down and ChIP assays. Several in vivo assays were used to assess the selectivity of the small-molecule compound VE-821 in HCC and to confirm the absence of general toxicity in animal models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>GRSF1 was frequently increased in HCC tissue and cells and was associated with worse clinical outcomes. GRSF1 functions as a novel oncogenic RBP by enhancing YY1 mRNA stability, and the GUUU motifs within the YY1 3`UTR 2663-2847 were the specific binding motifs for GRSF1. YY1 feedback promoted GRSF1 expression by binding to the GRSF1 promoter. In addition, YY1 was a critical target of miR-30e-5p, which was confirmed in this study to inhibit HCC hepatocarcinogenesis. GRSF1 and miR-30e-5p competitively regulated YY1 by binding to its 3`UTR 2663-2847 region. Finally, we identified that VE-821 blocked HCC progression by inhibiting the GRSF1\/YY1 pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study revealed the interaction network among GRSF1, YY1 and miR-30e-5p, providing new insight into HCC pathogenesis, and indicated that VE821 may serve as a novel agent with potential for HCC treatment through inhibition of the GRSF1\/YY1 axis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-021-02217-w","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T03:03:02Z","timestamp":1641610982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The RNA-binding protein GRSF1 promotes hepatocarcinogenesis via competitively binding to YY1 mRNA with miR-30e-5p"],"prefix":"10.1186","volume":"41","author":[{"given":"Lili","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"2217_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000343839","volume":"3","author":"RS Finn","year":"2012","unstructured":"Finn RS. Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer. 2012;3:247\u201356.","journal-title":"Liver Cancer."},{"key":"2217_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.patbio.2010.01.005","volume":"58","author":"MC Kew","year":"2010","unstructured":"Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol.Biol. 2010;58:273\u20137.","journal-title":"Pathol.Biol."},{"key":"2217_CR3","doi-asserted-by":"crossref","unstructured":"Kudo M. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. Oncology. 2017; 93.","DOI":"10.1159\/000481244"},{"key":"2217_CR4","first-page":"829","volume":"15","author":"S Gerstberger","year":"2014","unstructured":"Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat. Rev. Genet. 2014;15:829\u201345.","journal-title":"Genet."},{"key":"2217_CR5","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.febslet.2008.03.004","volume":"582","author":"T Glisovic","year":"2008","unstructured":"Glisovic T, Bachorik JL, Yong J, Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 2008;582:1977\u201386.","journal-title":"FEBS Lett."},{"key":"2217_CR6","doi-asserted-by":"crossref","unstructured":"Dreyfuss G, Kim VN, Kataoka N. Messenger RNA binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 2002; 3:195\u2013205.","DOI":"10.1038\/nrm760"},{"issue":"3","key":"2217_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41576-020-00302-y","volume":"22","author":"F Gebauer","year":"2021","unstructured":"Gebauer F, Schwarzl T, Valc\u00e1rcel J, Hentze MW. RNA-binding proteins in human genetic disease. Nat Rev Genet. 2021;22(3):185\u201398.","journal-title":"Nat Rev Genet."},{"key":"2217_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2020.09.020","volume":"496","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Z. RNA binding proteins: Linking mechanotransduction and tumor metastasis. Cancer Lett. 2021;496:30\u201340.","journal-title":"Cancer Lett."},{"issue":"19","key":"2217_CR9","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1007\/s00018-019-03163-9","volume":"76","author":"PD Vos","year":"2019","unstructured":"Vos PD, Leedman PJ, Filipovska A, Rackham O. Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer. Cell Mol Life Sci. 2019;76(19):3745\u201352.","journal-title":"Cell Mol Life Sci."},{"issue":"2","key":"2217_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41375-020-01066-4","volume":"35","author":"IA Elcheva","year":"2021","unstructured":"Elcheva IA, Spiegelman VS. Targeting RNA-binding proteins in acute and chronic leukemia. Leukemia. 2021;35(2):360\u201376.","journal-title":"Leukemia."},{"issue":"9","key":"2217_CR11","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1002\/jcp.30311","volume":"236","author":"A Bitaraf","year":"2021","unstructured":"Bitaraf A, Razmara E, Bakhshinejad B, Yousefi H, Vatanmakanian M, Garshasbi M, et al. The oncogenic and tumor suppressive roles of RNA-binding proteins in human cancers. J Cell Physiol. 2021;236(9):6200\u201324.","journal-title":"J Cell Physiol."},{"key":"2217_CR12","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1038\/s41388-021-01689-6","volume":"40","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li X, Zhang H, Zhang M, Wei Y. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. Oncogene. 2021;40:2230\u201342.","journal-title":"Oncogene."},{"key":"2217_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4161\/rna.6.4.8841","volume":"6","author":"PA Galante","year":"2009","unstructured":"Galante PA, Sandhu D, de Sousa AR, Gradassi M, Slager N, Vogel C, et al. A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue: Identification of potential players in tumor formation. RNA Biol. 2009;6:426\u201333.","journal-title":"RNA Biol."},{"key":"2217_CR14","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/nar\/gkz082","volume":"47","author":"JH Noh","year":"2019","unstructured":"Noh JH, Kim KM, Pandey PR, Noren Hooten N, Munk R, Kundu G, et al. Loss of RNA-binding protein GRSF1 activates mTOR to elicit a proinflammatory transcriptional program. Nucleic Acids Res. 2019;47:2472\u201386.","journal-title":"Nucleic Acids Res."},{"key":"2217_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41419-019-1841-5","volume":"10","author":"Q Sun","year":"2019","unstructured":"Sun Q, Yang Z, Li P, Wang X, Sun L, Wang S, et al. A novel miRNA identified in GRSF1 complex drives the metastasis via the PIK3R3\/AKT\/NF-\u03baB and TIMP3\/MMP9 pathways in cervical cancer cells. Cell Death Dis. 2019;10:636.","journal-title":"Cell Death Dis."},{"key":"2217_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/15548627.2018.1539590","volume":"15","author":"Z Yang","year":"2019","unstructured":"Yang Z, Sun Q, Guo J, Wang S, Song G, Liu W, et al. GRSF1-mediated MIR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy. 2019;15:668\u201385.","journal-title":"Autophagy."},{"key":"2217_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12885-015-1043-1","volume":"15","author":"J Wang","year":"2015","unstructured":"Wang J, Zhou L, Li Z, Zhang T, Liu W, Liu Z, et al. YY1 suppresses FEN1 over-expression and drug resistance in breast cancer. BMC Cancer. 2015;15:50.","journal-title":"BMC Cancer."},{"key":"2217_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pharmthera.2015.01.011","volume":"150","author":"B Bonavida","year":"2015","unstructured":"Bonavida B, Kaufhold S. Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target. Pharmacol Therapeut. 2015;150:149\u201368.","journal-title":"Pharmacol Therapeut."},{"key":"2217_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1568009615666150131124200","volume":"15","author":"JM Shi","year":"2015","unstructured":"Shi JM, Hao AX, Zhang Q, Sui GC. The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies. Curr Cancer Drug Tar. 2015;15:145\u201357.","journal-title":"Curr Cancer Drug Tar."},{"key":"2217_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/gutjnl-2019-318830","volume":"69","author":"WP Xu","year":"2020","unstructured":"Xu WP, Liu JP, Feng JF, Zhu CP, Yang Y, Zhou WP, et al. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut. 2020;69:1309\u201321.","journal-title":"Gut."},{"key":"2217_CR21","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1038\/s41418-020-0575-3","volume":"27","author":"G Liu","year":"2020","unstructured":"Liu G, Ouyang X, Sun Y, Xiao Y, You B, Gao Y, et al. The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR\/PHLPP\/p-AKT\/\u03b2-catenin signaling. Cell Death Differ. 2020;27:3258\u201372.","journal-title":"Cell Death Differ."},{"key":"2217_CR22","first-page":"2433","volume":"53","author":"LL Han","year":"2018","unstructured":"Han LL, Yin XR, Zhang SQ. miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2. Int J Oncol. 2018;53:2433\u201344.","journal-title":"Int J Oncol."},{"key":"2217_CR23","doi-asserted-by":"publisher","first-page":"BSR20194309","DOI":"10.1042\/BSR20194309","volume":"40","author":"W Hu","year":"2020","unstructured":"Hu W, Yao W, Li H, Chen L. MiR-30e-5p inhibits the migration and invasion of nasopharyngeal carcinoma via regulating the expression of MTA1. Biosci Rep. 2020;40:BSR20194309.","journal-title":"Biosci Rep."},{"key":"2217_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.yexcr.2017.11.027","volume":"362","author":"G Xu","year":"2018","unstructured":"Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R, et al. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1\/JAK\/STAT3 signaling. Exp Cell Res. 2018;362:268\u201378.","journal-title":"Exp Cell Res."},{"key":"2217_CR25","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1158\/1078-0432.CCR-18-0716","volume":"25","author":"AD Saleh","year":"2019","unstructured":"Saleh AD, Cheng H, Martin SE, Si H, Ormanoglu P, Carlson S, et al. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer. Clin Cancer Res. 2019;25:2860\u201373.","journal-title":"Clin Cancer Res."},{"key":"2217_CR26","doi-asserted-by":"crossref","unstructured":"Guo J, Lv J, Liu M, Tang H. miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy. J Biol Chem. 2015; 290: 30342-30350.","DOI":"10.1074\/jbc.M115.691857"},{"key":"2217_CR27","doi-asserted-by":"crossref","unstructured":"Han L, Huang C, Zhang S. The RNA-binding protein SORBS2 suppresses hepatocellular carcinoma tumourigenesis and metastasis by stabilizing RORA mRNA. Liver Int. 2019;39:2190\u2013203","DOI":"10.1111\/liv.14202"},{"key":"2217_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/1878-0261.12593","volume":"14","author":"SL Chen","year":"2020","unstructured":"Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, et al. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras\/Raf\/ERK pathways. Mol Oncol. 2020;14:373\u201386.","journal-title":"Mol Oncol."},{"key":"2217_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-017-0620-3","volume":"36","author":"XJ Zhou","year":"2017","unstructured":"Zhou XJ, Wu J, Shi L, Li XX, Zhu L, Sun X, et al. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer. J Exp Clin Cancer Res. 2017;36:149.","journal-title":"J Exp Clin Cancer Res."},{"key":"2217_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/0008-5472.CAN-19-2115","volume":"80","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zhao Y, Huan L, Zhao J, Zhou Y, Xu L, et al. An LTR Retrotransposon-Derived Long Noncoding RNA lncMER52A Promotes Hepatocellular Carcinoma Progression by Binding p120-Catenin. Cancer Res. 2020;80:976\u201387.","journal-title":"Cancer Res."},{"key":"2217_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13046-020-01551-9","volume":"39","author":"Z Rong","year":"2020","unstructured":"Rong Z, Wang Z, Wang X, Qin C, Geng W. Molecular interplay between linc01134 and YY1 dictates hepatocellular carcinoma progression. J Exp Clin Cancer Res. 2020;39:61.","journal-title":"J Exp Clin Cancer Res."},{"key":"2217_CR32","doi-asserted-by":"publisher","first-page":"7599","DOI":"10.7150\/thno.34931","volume":"9","author":"Y Li","year":"2019","unstructured":"Li Y, Kasim V, Yan X, Li L, Meliala ITS, Huang C, et al. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1\u03b2-induced fatty acid oxidation. Theranostics. 2019;9:7599\u2013615.","journal-title":"Theranostics."},{"key":"2217_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12508","volume":"51","author":"R Hu","year":"2018","unstructured":"Hu R, Zhu X, Chen C, Xu R, Li Y, Xu W. RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs. Cell Prolif. 2018;51:e12508.","journal-title":"Cell Prolif."},{"key":"2217_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/cdd.2014.176","volume":"22","author":"Y Kuwano","year":"2015","unstructured":"Kuwano Y, Nishida K, Kajita K, Satake Y, Akaike Y, Fujita K, et al. Transformer 2\u03b2 and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA. Cell Death Differ. 2015;22:815\u201325.","journal-title":"Cell Death Differ."},{"key":"2217_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10529-018-2512-9","volume":"40","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Yang L, Ling C, Heng W. HuR facilitates cancer stemness of lung cancer cells via regulating miR-873\/CDK3 and miR-125a-3p\/CDK3 axis. Biotechnol Lett. 2018;40:623\u201331.","journal-title":"Biotechnol Lett."},{"key":"2217_CR36","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1128\/MCB.05955-11","volume":"31","author":"K Tominaga","year":"2011","unstructured":"Tominaga K, Srikantan S, Lee EK, Subaran SS, Martindale JL, Abdelmohsen K, et al. Competitive regulation of nucleolin expression by HuR and miR-494. Mol Cell Biol. 2011;31:4219\u201331.","journal-title":"Mol Cell Biol."},{"key":"2217_CR37","doi-asserted-by":"crossref","unstructured":"YT, Xiao YS, Li J, Liu P, Liu ZS, Liu QY. Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p\/MAPK\/NFAT5 pathway. J Exp Clin Cancer Res. 2017; 36(1):148.","DOI":"10.1186\/s13046-017-0618-x"},{"key":"2217_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology."},{"key":"2217_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/1878-0261.12402","volume":"13","author":"MH Dias","year":"2019","unstructured":"Dias MH, Fonseca CS, Zeidler JD, Albuquerque LL, da Silva MS, Cararo-Lopes E, et al. Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors. Mol Oncol. 2019;13:290\u2013306.","journal-title":"Mol Oncol."},{"key":"2217_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3390\/diagnostics10020121","volume":"10","author":"BT Burgess","year":"2020","unstructured":"Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM. Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics (Basel). 2020;10:121.","journal-title":"Diagnostics (Basel)."}],"updated-by":[{"DOI":"10.1186\/s13046-022-02392-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02217-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02217-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02217-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T02:09:54Z","timestamp":1653444594000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02217-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2217"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02217-w","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13046-022-02392-4","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-022-02392-4","URL":"https:\/\/doi.org\/10.1186\/s13046-022-02392-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}